Interactive Financial Charts Not Available

Titan Bio-Tech (TITANBIO) | Financial Analysis & Statements

Titan Bio-Tech Ltd. | Small-cap | Healthcare

₹471.10

6.87%

Titan Bio-Tech vs Biocon Titan Bio-Tech vs OneSource Specialty Titan Bio-Tech vs Dishman Carbogen Titan Bio-Tech vs Zota Health Care Titan Bio-Tech vs Panacea Biotec Titan Bio-Tech vs NIFTY 50 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 351.7M

Gross Profit 201.6M 57.31%

Operating Income 37.3M 10.60%

Net Income 40.5M 11.51%

Balance Sheet Metrics

Total Assets 1.7B

Total Liabilities 213.0M

Shareholders Equity 1.5B

Debt to Equity 0.14

Cash Flow Metrics

Operating Cash Flow 45.6M

Free Cash Flow 12.2M

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Titan Bio-Tech Income Statement From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Revenue i	1.6B	1.6B	1.4B	1.2B	1.4B
Cost of Goods Sold i	726.3M	937.4M	856.4M	705.3M	752.8M
Gross Profit i	838.2M	703.4M	583.6M	530.2M	669.5M
Gross Margin % i	53.6%	42.9%	40.5%	42.9%	47.1%
Operating Expenses
Research & Development i	-	-	-	-	-
Selling, General & Administrative i	-	111.6M	96.4M	65.7M	55.8M
Other Operating Expenses i	320.2M	8.4M	9.1M	9.4M	5.9M
Total Operating Expenses i	320.2M	120.0M	105.5M	75.1M	61.7M
Operating Income i	212.6M	309.5M	270.0M	289.0M	443.7M
Operating Margin % i	13.6%	18.9%	18.7%	23.4%	31.2%
Non-Operating Items
Interest Income i	-	857.0K	443.0K	1.1M	573.2K
Interest Expense i	8.0M	9.4M	5.6M	6.9M	14.8M
Other Non-Operating Income	-	-	-	-	-
Pre-tax Income i	243.7M	315.3M	281.2M	289.7M	427.1M
Income Tax i	61.0M	78.7M	70.9M	72.8M	110.0M
Effective Tax Rate % i	25.0%	24.9%	25.2%	25.1%	25.8%
Net Income i	215.3M	248.5M	248.4M	216.8M	317.1M
Net Margin % i	13.8%	15.1%	17.3%	17.6%	22.3%
Key Metrics
EBITDA i	293.4M	352.4M	313.1M	320.3M	471.3M
EPS (Basic) i	-	₹30.07	₹30.06	₹26.24	₹36.71
EPS (Diluted) i	-	₹30.07	₹30.06	₹26.24	₹36.71
Basic Shares Outstanding i	-	8263700	8263700	8263834	8263700
Diluted Shares Outstanding i	-	8263700	8263700	8263834	8263700

Income Statement Trend

Titan Bio-Tech Balance Sheet From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Assets
Current Assets
Cash & Equivalents i	51.3M	28.4M	48.6M	68.1M	54.5M
Short-term Investments i	4.3M	-	-	-	1.8M
Accounts Receivable i	188.2M	186.6M	210.1M	163.6M	181.0M
Inventory i	507.2M	458.8M	365.6M	346.8M	325.4M
Other Current Assets	38.7M	50.5M	43.2M	59.0M	27.3M
Total Current Assets i	790.4M	721.7M	683.1M	637.6M	588.3M
Non-Current Assets
Property, Plant & Equipment i	571.6M	519.4M	22.9M	348.8M	335.1M
Goodwill i	1.2M	950.0K	852.0K	1.0M	917.3K
Intangible Assets i	1.2M	950.0K	852.0K	1.0M	917.3K
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	-	-	1.0K	1.1M	-
Total Non-Current Assets i	956.7M	844.1M	662.1M	443.4M	418.9M
Total Assets i	1.7B	1.6B	1.3B	1.1B	1.0B
Liabilities
Current Liabilities
Accounts Payable i	52.2M	33.7M	55.5M	41.6M	37.1M
Short-term Debt i	23.8M	71.6M	70.8M	67.4M	85.4M
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	32.7M	23.9M	24.3M	17.5M	17.9M
Total Current Liabilities i	177.4M	191.3M	203.5M	169.5M	192.8M
Non-Current Liabilities
Long-term Debt i	4.2M	11.5M	14.3M	21.9M	62.5M
Deferred Tax Liabilities i	15.2M	13.7M	12.1M	12.8M	13.9M
Other Non-Current Liabilities	-	100.0M	1.0K	0	-
Total Non-Current Liabilities i	35.7M	140.0M	42.5M	49.0M	89.6M
Total Liabilities i	213.0M	331.3M	246.0M	218.5M	282.4M
Equity
Common Stock i	82.6M	82.6M	82.6M	82.6M	82.6M
Retained Earnings i	-	1.2B	928.2M	759.9M	517.0M
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	1.5B	1.3B	1.1B	862.4M	724.8M
Key Metrics
Total Debt i	28.0M	83.0M	85.1M	89.3M	147.9M
Working Capital i	613.0M	530.5M	479.6M	468.1M	395.5M

Balance Sheet Composition

Titan Bio-Tech Cash Flow Statement From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Operating Activities
Net Income i	243.7M	315.3M	281.2M	289.7M	427.1M
Depreciation & Amortization i	-	-	-	-	-
Stock-Based Compensation i	-	-	-	-	-
Working Capital Changes i	-53.9M	-51.0M	-43.5M	-58.2M	-184.1M
Operating Cash Flow i	197.8M	276.0M	245.1M	240.2M	259.6M
Investing Activities
Capital Expenditures i	-85.3M	-86.7M	-131.6M	-136.8M	-48.6M
Acquisitions i	-	-	-	-	-
Investment Purchases i	-13.2M	-116.0M	-75.6M	-27.6M	-
Investment Sales i	150.0K	-	-	-	-
Investing Cash Flow i	-98.3M	-202.7M	-207.2M	-164.4M	-48.6M
Financing Activities
Share Repurchases i	-	-	-	-	-
Dividends Paid i	-16.5M	-14.9M	-12.4M	-12.4M	-8.3M
Debt Issuance i	-	1.5M	-	27.3M	-
Debt Repayment i	-2.7M	-	-7.8M	-7.5M	-97.5M
Financing Cash Flow i	-67.2M	-13.2M	-17.7M	110.4M	-105.8M
Free Cash Flow i	106.8M	14.6M	77.1M	83.6M	142.2M
Net Change in Cash i	32.3M	60.2M	20.2M	186.2M	105.2M

Cash Flow Trend

Titan Bio-Tech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 18.08

Price to Book 2.54

Price to Sales 2.44

Profitability Ratios

Profit Margin 13.76%

Operating Margin 16.31%

Return on Equity 14.04%

Return on Assets 12.32%

Financial Health

Current Ratio 4.46

Debt to Equity 1.82

Beta 0.32

Per Share Data

EPS (TTM) ₹26.05

Book Value per Share ₹185.75

Revenue per Share ₹193.45

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
titanbio	3.9B	18.08	2.54	14.04%	13.76%	1.82
Biocon	479.6B	112.27	1.99	3.66%	2.44%	66.26
OneSource Specialty	215.4B	-1,151.60	3.65	-0.31%	-0.85%	16.03
Dishman Carbogen	42.0B	1,274.29	0.72	0.06%	3.60%	40.97
Zota Health Care	35.4B	-66.66	22.82	-24.83%	-20.55%	65.72
Panacea Biotec	25.8B	91.93	3.07	-1.05%	-1.50%	2.67

Financial data is updated regularly. All figures are in the company's reporting currency.